EVALUATION OF RISK AND PROGNOSTIC FACTORS OF CARBAPENEM RESISTANT ACINETOBACTER BAUMANNII INFECTIONS IN INTENSIVE CARE UNIT.

  • İzmir Menemen State Hospital, Department of Medical Microbiology, İzmir, Turkey.
  • İzmir Menemen State Hospital, Clinic of Infectious Disease, İzmir, Turkey.
  • İzmir Cigli Education and Research Hospital, Department of Anesthesiology and Critical Care Medicine, İzmir, Turkey.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Objective: Multi-drug resistant Acinetobacter baumannii isolation is increasing among hospital infections. This study aims to examine the factors affecting the morbidity and mortality together with the selections and periods of the treatment applied on multi-drug resistant and extreme drug resistant A. baumannii infections that develop in intensive care unit patients. Materials and Methods: Of the 20 cases involved in the study (10 male, 10 female; mean age 71,9 ?16 years), laboratory and treatment results as well were assessed during the treatment. Antibiotic susceptibility test was practiced with disk diffusion test in A. baumannii strains and it was practiced by using E test for colistin, meropenem, and imipenem. Results: The infections detected as ventilator associated pneumonia (VAP) were determined on the 14th day of hospitalization on the average, and the follow up period is 40,8 days in the intensive care unit (ICU). The values of Acute Physiology and Chronic Health Evaluation II (APACHE II) was 26,8 ?3,2. The most preferred combinations are colistin-sulbactam and colistin-carbapenem. In three of the cases, the isolates were resistant to all antibiotics. During colistin treatment, dermatitis was observed in two subjects and nephrotoxicity in five subjects. Thirteen of the subjects were lost because of not eradicating the active microorganism resistant to antibiotics. Conclusion: In our study it was concluded that early diagnosis and treatment and needed isolation precautions are important in infection follow-up in the infections caused by A. baumannii strains that have an important role in intensive care infections. 

1.?????? Dijkshoorn L,?Nemec A &?Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 2007;?5: 939?51.
2.?????? Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: Emergence of a Successful Pathogen. Clin Microbiol Rev 2008; 21(3):?538-82.
  1. Phumisantiphong U, Diraphat P, Utrarachkij F, Uaratanawong S, Siripanichgon K. Clonal spread of carbapenem resistant Acinetobacter baumannii in the patients and their environment at BMA Medical College and Vajira Hospital. J Med Assoc Thai 2009; 92 (7): 173-80.
  2. Ece G,Erac B, Cetin HY, Ece C, and Baysak A. Antimicrobial Susceptibility and Clonal Relation Between Acinetobacter baumannii Strains at a Tertiary Care Center in Turkey. Jundishapur J Microbiol 2015; 8(2): e156122.
  3. Kim YA, Choi JY, Kim CK, et al. Risk factors and outcomes of bloodstream infections with metallo-beta-lactamase-producing Acinetobacter. Scand J Infect Dis 2008; 40(3): 234-40.
  4. Performance standards for antimicrobial susceptibility testing, Twenty-Fourth Informational Supplement 2014, M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
  5. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-74.
  6. Choi JY, Park YS, Kim CO, et al. Mortality risk factors of Acinetobacter baumannii bacteremia. Intern Med J 2005; 35(10): 599-603.
  7. FalagasME,?Rafailidis PI. Attributable mortality of?Acinetobacter?baumannii: no longer a controversial issue. Crit Care?2007; 11(3): 134.
  8. Mulin?B,?Talon D,?Viel JF,?et al. Risk factors for?nosocomial?colonization?with multiresistant Acinetobacter?baumannii. Eur J Clin Microbiol Infect Dis 1995; 14(7): 569-76.
  1. Ulu Kili? A, Ahmed SS, Alp E, Doğanay M. Challenge of intensive care unit-acquired infections and Acinetobacter baumannii in developing countries. OA Critical Care 2013; 1(1): 2.
  2. Garnacho-Montero J, Ortiz-Leyba C, Fern?ndez- Hinojosa E, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 2005; 31: 649-55.
  3. Tejerina E, Frutos-Vivar F, Restrepo MI, et al. Incidence, risk factors, and outcome of ventilator-associated pneumonia. J Crit Care 2006; 21: 56-65.
  4. Gamble JM,Eurich DT,?Marrie TJ,?Majumdar SR. Admission hypoglycemia and increased mortality in patients hospitalized with pneumonia. Am J Med?2010; 123(6):556.e11-6. doi: 10.1016/j.amjmed.2009.11.021.
  5. Inchai J,?Pothirat C,?Bumroongkit C,?Limsukon A,?Khositsakulchai?W and Liwsrisakun C.?Prognostic factors associated with mortality of drug-resistant?Acinetobacter baumannii?ventilator-associated pneumonia. J Intensive Care?2015; 3:9.
  1. Bekaert M, Timsit JF, Vansteelandt S, et al. Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. Am J Respir Crit Care Med 2011;184:1133?9.
  2. Şeng?l A, Şeng?l E, Barış SA, Hayırlıoğlu N. Assesment of the factors associated with mortality in ventilator associated pneumonia of multidrug resistance Acinetobacter baumannii. Medical Journal of Kocaeli 2013; 1: 1-6
  3. Edis EC, Hatipoglu ON, Tansel O, Sut N. Acinetobacter pneumonia: Is the outcome different from the pneumonias caused by other agents. Ann Thorac Med 2010; 5: 92-6.
  4. Grupper M, Sprecher H, Mashiach T, Finkelstein R. Attributable mortality of nosocomial Acinetobacter bacteremia. Infect Control Hosp Epidemiol 2007; 28(3): 293-8.
  5. Blot S, Vandewoude K, Colardyn F. Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study. Intensive Care Med 2003; 29(3): 471-5.
  6. Alp E, Yerer M, Kocag?z S, et al. The risk factors and spread of multidrug-resistant Acinetobacter baumannii in intubated patients in a medical intensive care unit. Turk J Med Sci 2009; 39(5): 761-9.
  7. Higgins PG,?Dammhayn C,?Hackel M,?Seifert H. Global spread of carbapenem-resistant?Acinetobacter baumannii. J Antimicrob Chemother?2010; 65(2):233-8. doi: 10.1093/jac/dkp428
  1. Kim YJ, Kim SI, Kim YR, et al. Carbapenem-resistant Acinetobacter baumannii: diversity of resistant mechanisms and risk factors for infection. Epidemiol Infect 2012; 140: 137?45.
  2. Tseng YC, Wang JT, Wu FL, Chen YC, Chie WC, Chang SC. Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2007; 59(2): 181-90.
  3. Kwon KT, Oh WS, Song JH, et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother 2007; 59(3): 525-30.
  1. Ahmed SS, Alp E, Ulu-Kilic, A. et al. Spread of carbapenem-resistant international clones ofAcinetobacter baumannii?in Turkey and Azerbaijan: a collaborative study. Eur J Clin Microbiol Infect Dis 2016; 35: 1463. doi:10.1007/s10096-016-2685-x.
  2. Nhu NT, Lan NP, Campbell JI, et al. Emergence of carbapenem-resistant?Acinetobacter baumannii?as the major cause of ventilator-associated pneumonia in intensive care unit patients at an infectious disease hospital in southern. Vietnam?J Med Microbiol?2014; 63: 1386?94. doi:10.1099/jmm.0.076646-0.
  3. Le Minh V, Thi Khanh Nhu N, Vinh Phat VV, et al.In vitro?activity of colistin in antimicrobial combination against carbapenem-resistant?Acinetobacter baumannii?isolated from patients with ventilator-associated pneumonia in Vietnam.?J Med Microbiol 2015; 64(10): 1162-9. doi:10.1099/jmm.0.000137.
  4. Kiratisin P, Apisarnthanarak A. & Kaewdaeng S. Synergistic activities between carbapenems and other antimicrobial agents against Acinetobacter baumannii including multidrugresistant and extensively drug-resistant isolates. Int J Antimicrob Agents 2010; 36: 243?6.
  5. Aydemir H,Akduman D,? Piskin N, et al. Colistin?vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant?Acinetobacter baumannii?ventilator-associated pneumonia. Epidemiol & Infect 2013; 141 (6): 1214-22.

[Fulya Bayındır Bilman, Barış Ci?ek and Cem Ece. (2017); EVALUATION OF RISK AND PROGNOSTIC FACTORS OF CARBAPENEM RESISTANT ACINETOBACTER BAUMANNII INFECTIONS IN INTENSIVE CARE UNIT. Int. J. of Adv. Res. 5 (Jun). 1261-1268] (ISSN 2320-5407). www.journalijar.com

Fulya Bay?nd?r Bilman
zmir Menemen State Hospital, Department of Medical Microbiology, ?zmir, Turkey

DOI:

Article DOI: 10.21474/IJAR01/4533      
DOI URL: https://dx.doi.org/10.21474/IJAR01/4533

Download Full Paper

Download PDF No. of Downloads: 18 | No. of Views: 117